Hiral D. Parekh

Hiral D. Parekh

Auto-generated profile, based on publicly available information

Hiral D. Parekh

University of Florida Health Cancer Center, Gainesville, FL

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2019 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
AFAaron J Franke
Aaron J Franke
WIWilliam Paul Skelton IV
William Paul Skelton IV
JSJason S Starr
Jason S Starr
HPHiral Parekh
Hiral Parekh
JLJames J Lee
James J Lee
TGThomas J George
Thomas J George
Colorectal cancer (CRC) remains a leading cause of cancer-related deaths in the United States. Although immunotherapy has dramatically changed the landscape of treatment for many advanced cancers, the benefit in CRC has thus far been limited to patients with microsatellite instability high (MSI-H):DNA mismatch repair–deficient (dMMR) tumors. Recent studies in the refractory CRC setting have led to US Food and Drug Administration approvals for pembrolizumab as well as nivolumab (with or without ipilimumab) for tumors harboring an MSI-H:dMMR molecular profile. Several randomized controlled trials are underway to move immunotherapy into the frontline for metastatic cancer (with or without chemotherapy) and the adjuvant setting. Awareness of these studies is critical given the relatively low incidence (approximately 3%–5%) of MSI-H:dMMR in advanced or metastatic CRC to support study completion, because the results could be potentially practice changing. The real challenge in this disease is related to demonstrating the benefit of immunotherapy for the vast majority of patients with CRC not harboring MSI-H:dMMR. Given the rapid pace of scientific changes, this article provides a narrative review regarding the current landscape of immunotherapy for CRC. Particular attention is paid to the currently available data that inform today’s clinical practice along with upcoming randomized controlled trials that may soon dramatically change the treatment landscape for CRC.

1 March 2018 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
AFAaron J. Franke
Aaron J. Franke
HPHiral Parekh
Hiral Parekh
JSJason S. Starr
Jason S. Starr
STSanda A. Tan
Sanda A. Tan
AIAtif Iqbal
Atif Iqbal
TGThomas J George
Thomas J George

1 August 2018 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
WHWissam Hanayneh
Wissam Hanayneh
JSJason Starr
Jason Starr
TGThomas J George
Thomas J George
HPHiral Parekh
Hiral Parekh
Gastrointestinal stromal tumors (GISTs) are rare tumors of gastrointestinal (GI) tract with mesenchymal cell origin. Extragastrointestinal stromal tumors (EGISTs) are unusual tumors that exhibit the same immunohistochemical and genetic abnormalities as GISTs and most commonly affect the omentum and mesentery. EGISTs of the pelvis and the female reproductive system are exceedingly rare and a frequent diagnostic pitfall. In this report, we present two cases of EGISTs along with a review of the literature.

1 February 2019 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
NKNils Kroeger
Nils Kroeger
HLHaoran Li
Haoran Li
GVGuillermo De Velasco
Guillermo De Velasco
FDFrede Donskov
Frede Donskov
Hao-Wen SimHao-Wen Sim
Hao-Wen Sim
DHDaniel Yick Chin Heng
Daniel Yick Chin Heng

7 November 2017 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
WSWilliam Paul Skelton
William Paul Skelton
HPHiral Parekh
Hiral Parekh
JSJason S. Starr
Jason S. Starr
JTJose Trevino
Jose Trevino
JCJessica Cioffi
Jessica Cioffi
TGThomas J George
Thomas J George

17 September 2015 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
HPHiral Parekh
Hiral Parekh
BRBrian I Rini
Brian I Rini
(2015). Emerging therapeutic approaches in renal cell carcinoma. Expert Review of Anticancer Therapy: Vol. 15, No. 11, pp. 1305-1314. doi: 10.1586/14737140.2015.1090315